Loading...

Lattice Biologics

DB:B5G2
Snowflake Description

Mediocre balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
B5G2
DB
CA$2M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and cartilage regeneration worldwide. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
  • Lattice Biologics has significant price volatility in the past 3 months.
B5G2 Share Price and Events
7 Day Returns
-12.5%
DB:B5G2
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-53.3%
DB:B5G2
-9.2%
DE Biotechs
-6.7%
DE Market
B5G2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Lattice Biologics (B5G2) -12.5% -17.6% 366.7% -53.3% -91.7% -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • B5G2 underperformed the Biotechs industry which returned -9.2% over the past year.
  • B5G2 underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
B5G2
Industry
5yr Volatility vs Market
Related Companies

B5G2 Value

 Is Lattice Biologics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Lattice Biologics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Lattice Biologics.

DB:B5G2 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 12.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:B5G2
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (117.62%))
2.212
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (2 * 5.96%)
12.15%

Discounted Cash Flow Calculation for DB:B5G2 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Lattice Biologics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:B5G2 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 12.15%)
2019 0.38 Est @ 91.99% 0.34
2020 0.62 Est @ 64.46% 0.50
2021 0.91 Est @ 45.19% 0.64
2022 1.19 Est @ 31.7% 0.75
2023 1.46 Est @ 22.26% 0.82
2024 1.69 Est @ 15.65% 0.85
2025 1.87 Est @ 11.02% 0.84
2026 2.02 Est @ 7.78% 0.81
2027 2.13 Est @ 5.52% 0.76
2028 2.21 Est @ 3.93% 0.70
Present value of next 10 years cash flows $7.01
DB:B5G2 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $2.21 × (1 + 0.23%) ÷ (12.15% – 0.23%)
$18.61
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $18.61 ÷ (1 + 12.15%)10
$5.91
DB:B5G2 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $7.01 + $5.91
$12.92
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $12.92 / 93.46
$0.25
DB:B5G2 Discount to Share Price
Calculation Result
Exchange Rate USD/CAD
(Reporting currency to currency of TSXV:LBL)
1.338
Value per Share
(CAD)
= Value per Share in USD x Exchange Rate (USD/CAD)
= $0.14 x 1.338
CA$0.18
Non-primary Listing Adjustment Factor 1 share in DB:B5G2 represents 0.56x of TSXV:LBL
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.56x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (CAD) x Listing Adjustment Factor
= CA$ 0.18 x 0.56
€0.10
Value per share (EUR) From above. €0.10
Current discount Discount to share price of €0.01
= -1 x (€0.01 - €0.10) / €0.10
86.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Lattice Biologics is available for.
Intrinsic value
>50%
Share price is €0.014 vs Future cash flow value of €0.10356
Current Discount Checks
For Lattice Biologics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Lattice Biologics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Lattice Biologics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Lattice Biologics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Lattice Biologics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:B5G2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.01
TSXV:LBL Share Price ** TSXV (2019-04-18) in CAD CA$0.03
TSXV:LBL Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.748 $0.02
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Lattice Biologics.

DB:B5G2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:LBL Share Price ÷ EPS (both in USD)

= 0.02 ÷ -0.01

-1.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lattice Biologics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Lattice Biologics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Lattice Biologics's expected growth come at a high price?
Raw Data
DB:B5G2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Lattice Biologics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Lattice Biologics's assets?
Raw Data
DB:B5G2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.06
TSXV:LBL Share Price * TSXV (2019-04-18) in CAD CA$0.03
TSXV:LBL Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.748 $0.02
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:B5G2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:LBL Share Price ÷ Book Value per Share (both in USD)

= 0.02 ÷ -0.06

-0.32x

* Primary Listing of Lattice Biologics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lattice Biologics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess Lattice Biologics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Lattice Biologics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

B5G2 Future Performance

 How is Lattice Biologics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lattice Biologics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.4%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Lattice Biologics expected to grow at an attractive rate?
  • Unable to compare Lattice Biologics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Lattice Biologics's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Lattice Biologics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:B5G2 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:B5G2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:B5G2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:B5G2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 0 -1
2018-09-30 1 0 -1
2018-06-30 1 0 -2
2018-03-31 2 0 0
2017-12-31 2 0 0
2017-09-30 3 -1 -2
2017-06-30 3 -1 -2
2017-03-31 3 -2 -5
2016-12-31 4 -2 -5
2016-09-30 4 -2 -8
2016-06-30 4 -2 -8
2016-03-31 4 -2 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Lattice Biologics is high growth as no earnings estimate data is available.
  • Unable to determine if Lattice Biologics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:B5G2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Lattice Biologics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:B5G2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:B5G2 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.02
2018-03-31 0.00
2017-12-31 -0.01
2017-09-30 -0.02
2017-06-30 -0.03
2017-03-31 -0.08
2016-12-31 -0.09
2016-09-30 -0.16
2016-06-30 -0.25
2016-03-31 -0.16

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Lattice Biologics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of B5G2’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Lattice Biologics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Lattice Biologics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Lattice Biologics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Lattice Biologics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

B5G2 Past Performance

  How has Lattice Biologics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Lattice Biologics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Lattice Biologics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Lattice Biologics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Lattice Biologics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Lattice Biologics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Lattice Biologics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:B5G2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.26 -1.21 1.78 0.01
2018-09-30 1.16 -1.23 1.87 0.00
2018-06-30 1.28 -1.86 1.78 -0.04
2018-03-31 1.77 0.36 1.95 0.01
2017-12-31 2.21 -0.44 2.61 0.08
2017-09-30 2.74 -1.52 3.02 0.22
2017-06-30 3.07 -2.07 3.85 0.29
2017-03-31 3.36 -4.91 4.06 0.25
2016-12-31 3.60 -5.06 3.95 0.19
2016-09-30 3.78 -7.85 5.18 0.07
2016-06-30 4.08 -7.59 4.65 0.05
2016-03-31 4.02 -7.49 4.55 0.04
2015-12-31 4.08 -7.19 4.28 0.02
2015-09-30 4.19 -4.06 3.01
2014-12-31 6.11 -1.50 2.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Lattice Biologics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Lattice Biologics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Lattice Biologics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Lattice Biologics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Lattice Biologics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

B5G2 Health

 How is Lattice Biologics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Lattice Biologics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Lattice Biologics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Lattice Biologics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Lattice Biologics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Lattice Biologics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Lattice Biologics Company Filings, last reported 3 months ago.

DB:B5G2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -5.43 2.05 0.00
2018-09-30 -5.32 2.03 0.01
2018-06-30 -5.10 2.53 0.00
2018-03-31 -4.54 2.51 0.00
2017-12-31 -4.34 2.44 0.01
2017-09-30 -4.26 2.41 0.02
2017-06-30 -3.42 2.51 0.02
2017-03-31 -6.58 2.81 0.03
2016-12-31 -5.97 2.91 0.00
2016-09-30 -5.89 2.96 0.05
2016-06-30 -6.15 4.45 0.31
2016-03-31 -4.97 4.32 0.52
2015-12-31 -4.01 3.95 0.37
2015-09-30 -3.89 4.39 0.05
2014-12-31 -0.11 2.84 0.27
  • Lattice Biologics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Lattice Biologics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Lattice Biologics has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Lattice Biologics has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -86.9% per year.
X
Financial health checks
We assess Lattice Biologics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Lattice Biologics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

B5G2 Dividends

 What is Lattice Biologics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Lattice Biologics dividends.
If you bought €2,000 of Lattice Biologics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Lattice Biologics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Lattice Biologics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:B5G2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:B5G2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Lattice Biologics has not reported any payouts.
  • Unable to verify if Lattice Biologics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Lattice Biologics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Lattice Biologics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Lattice Biologics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Lattice Biologics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Lattice Biologics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

B5G2 Management

 What is the CEO of Lattice Biologics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Guy Cook
COMPENSATION $381,500
AGE 53
TENURE AS CEO 5.3 years
CEO Bio

Mr. Guy S. Cook has been the Chief Executive Officer of Lattice Biologics Ltd. since December 23, 2013 and also serves as its President. Mr. Cook served as the Chief Executive Officer and Director of Blackstone Ventures Inc. since December 29, 2015. He founded Xtant Medical Holdings, Inc. (formerly Bacterin International Holdings, Inc.) in 1997 served as its Chairman, Chief Executive Officer and President from June 30, 2010 to April 5, 2013. He served as the Chief Scientific Officer of Xtant Medical Holdings, Inc. He served as the Chairman, Chief Executive Officer and President of K-Kitz, Inc. and Bacterin until June 30, 2010. He is considered an international expert in biofilm science and its application. He has more than 25 years of experience organizing, managing and running all aspects of start-up and mid-size businesses. He started his career as a product specialist in the Image Analysis Department of Laboratory Equipment Company in Chicago. Mr. Cook later became President of Delta Resources in Crystal Lake, Illinois, which specialized in developing customized image analysis solutions for the academic community. In 1996, he moved to Montana and worked as a Confocal Microscopist for the Center for Biofilm Engineering at the Montana State University where he developed several proprietary testing models for the medical device industry. He has been Director of Lattice Biologics Ltd since 2015. He served as Director of K-Kitz, Inc. and Bacterin until June 30, 2010. He served as a Director of Xtant Medical Holdings, Inc. from June 30, 2010 to April 5, 2013. He is widely published and was invited to speak at many prominent biofilm conferences, including the Anti-Infective Materials Seminar in Tokyo, Japan and the FDA-CDRH Antimicrobial Device Efficacy Testing Seminar. Mr. Cook attended University of Indiana and received Bachelor of Science degrees in Finance and Economics.

CEO Compensation
  • Guy's compensation has increased whilst company is loss making.
  • Insufficient data for Guy to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Guy Cook

TITLE
CEO, President & Director
COMPENSATION
$382K
AGE
53
TENURE
5.3 yrs
Board of Directors Tenure

Average tenure of the Lattice Biologics board of directors in years:

3
Average Tenure
  • The tenure for the Lattice Biologics board of directors is about average.
Board of Directors

Guy Cook

TITLE
CEO, President & Director
COMPENSATION
$382K
AGE
53
TENURE
4.3 yrs

Kerry Zang

TITLE
Chair of the Scientific Advisory Board
TENURE
1.8 yrs

Donald McInnes

TITLE
Director
AGE
54
TENURE
25.3 yrs

Kevin Loud

TITLE
Director
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. Aug 18 Buy Cheryl Farmer Individual 10. Aug 18 10. Aug 18 10,000 €0.03 €346
11. Jul 18 Buy Cheryl Farmer Individual 10. Jul 18 10. Jul 18 10,000 €0.05 €469
02. Jul 18 Buy Cheryl Farmer Individual 29. Jun 18 29. Jun 18 1,000 €0.05 €48
15. Jun 18 Buy Cheryl Farmer Individual 15. Jun 18 15. Jun 18 1,500 €0.07 €109
12. Jun 18 Buy Cheryl Farmer Individual 11. Jun 18 11. Jun 18 500 €0.06 €30
07. Jun 18 Buy Cheryl Farmer Individual 07. Jun 18 07. Jun 18 10,000 €0.05 €460
05. Jun 18 Buy Cheryl Farmer Individual 04. Jun 18 04. Jun 18 10,000 €0.05 €471
23. May 18 Buy Cheryl Farmer Individual 22. May 18 22. May 18 20,000 €0.05 €932
X
Management checks
We assess Lattice Biologics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Lattice Biologics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

B5G2 News

Simply Wall St News

B5G2 Company Info

Description

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and cartilage regeneration worldwide. The company offers AmnioBoost, an allograft amniotic fluid visco supplement for the treatment of joint pain associated with osteoarthritis, as well as traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.

Details
Name: Lattice Biologics Ltd.
B5G2
Exchange: DB
Founded:
CA$1,554,028
93,458,300
Website: http://www.latticebiologics.com
Address: Lattice Biologics Ltd.
512 East Madison Avenue,
Suite 101,
Belgrade,
Montana, 59714,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV LBL Voting Common Shares TSX Venture Exchange CA CAD 24. Dec 2015
OTCPK LBLT.F Voting Common Shares Pink Sheets LLC US USD 24. Dec 2015
DB B5G2 Voting Common Shares Deutsche Boerse AG DE EUR 24. Dec 2015
Number of employees
Current staff
Staff numbers
0
Lattice Biologics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 20:58
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/01/29
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.